Clarithromycin/clofazimine/rifabutin companion diagnostic - RedHill Biopharma/Quest Diagnostics

Drug Profile

Clarithromycin/clofazimine/rifabutin companion diagnostic - RedHill Biopharma/Quest Diagnostics

Alternative Names: RHB 104 companion diagnostic

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RedHill Biopharma
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Crohn's disease
  • Phase II Multiple sclerosis

Most Recent Events

  • 05 Sep 2017 Phase-III development is ongoing in USA, Canada, New Zealand, Australia, Bulgaria, Czech Republic, Poland, Serbia, Slovakia and Israel (NCT01951326)
  • 06 Oct 2016 RedHill Biopharma collaborates with Baylor College of Medicine to develop companion diagnostic for the fixed dose combination of clarithromycin/clofazimine/rifabutin
  • 03 Jun 2015 RedHill Biopharma receives a notice of patent allowance for clarithromycin/clofazimine/rifabutin companion diagnostic in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top